Reintroduction of the MFN model. The Trump Administration has revived the most-favored nation (MFN) drug pricing model as a seven-year test, which would tie US drug prices to the lowest prices paid by ...

In the second part of her Pharma Commerce video interview, Kirsten Newquist, Identiv’s CEO, describes why this technology is essential for pharmaceutical safety and efficacy.

The acquisition of Cryoport’s specialty courier business is now finalized, with a value of approximately $200 million.

In the first part of her Pharma Commerce video interview, Kirsten Newquist, Identiv’s CEO, defines the term, and explains how ...

In the final part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, illustrates how data-driven ...

A systematic review determines if adult patients with language barriers are less likely to use the video-based virtual care ...

In the third part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, comments on how mobile and digital solutions can be deployed effectively to close the gap in areas ...

An Applied Clinical Trials article explores the complex and often conflicting perspectives of sponsors, CROs, and research sites on fair market value in clinical trial budgeting, emphasizing the need ...

Ron Lanton, Partner, Lanton Law, weighs in on the potential international trade, pricing, and access implications of tying US drug costs to those in other developed countries under the Most Favored ...

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional ...